Table 2 Clinical characteristics at onset and treatment given before consolidation treatment

From: Stage 4 neuroblastoma: sequential hemi-body irradiation or high-dose chemotherapy plus autologous haemopoietic stem cell transplantation to consolidate primary treatment

 

Program-1

Program-2

 

Total=25

%

Total=34

%

Sex

 Male

14

56

19

56

 Female

11

44

15

44

Age ranges (months)

    

 12–24

9

36

11

32

 25–216

16

64

23

68

Primary tumour site

    

 Retroperitoneum/adrenal gland

22

88

27

79

 Other sites

3

12

7

21

Bone marrow infiltration

 Absent

6

24

8

23

 Present

19

76

23

77

Bone metastases

 Absent

5

20

4

12

 Present

20

80

30

88

LDH (56 evaluated)

 <2n

9

37

12

37

 ⩾2n

15

63

20

63

NSE (54 evaluated)

    

 <100 ng ml−1

10

43

12

39

 ⩾100 ng ml−1

13

57

19

61

Ferritin (47 evaluated)

    

 <143 ng ml−1

5

25

9

33

 ⩾143 ng ml−1

15

75

18

67

VMA/HVA ratio (44 evaluated)

 <1

10

62

18

64

 ⩾1

6

38

10

36

Mean dose of chemotherapy during induction phase

 <120%

11

58

19

70

 ⩾120%

8

42

9

30

Surgery on primary tumour site

 No

17

84

19

71

 Yes

2

16

9

29

  1. Abbreviations: LDH=lactate dehydrogenase; NSE=neuron-specific enolase; VMA=vanylmandelic acid; HVA=homovanillic acid.
  2. 47 patients who concluded the induction phase.
  3. The distribution of clinical variables at onset, the drug doses given, the number of patients who underwent surgery on the primary tumour site were similar in the two groups (P: NS for all variables).
Back to article page